By Lynda Williams, medwireNews Reporter
medwireNews: The first randomised controlled trial of a CAR T-cell therapy in solid tumours has achieved a significant improvement in progression-free survival for patients with advanced gastric or gastro-oesophageal junction cancer compared with physician’s choice of therapy.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Read the full story on the L’Institut Servier website
Image credit: © Crystal light / stock.adobe.com
